Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer

Immune checkpoint inhibitors (ICIs) are commonly used to treat patients with advanced urothelial cancer. However, a significant number of patients do not respond to ICI, and the lack of validated predictive biomarkers impedes the success of the ICI strategy alone or in combination with chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Parent, Pauline, Marcq, Gautier, Adeleke, Sola, Turpin, Anthony, Boussios, Stergios, Rassy, Elie, Penel, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486227/
https://www.ncbi.nlm.nih.gov/pubmed/37692364
http://dx.doi.org/10.1177/17588359231192402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486227/
https://www.ncbi.nlm.nih.gov/pubmed/37692364
http://dx.doi.org/10.1177/17588359231192402

Ejemplares similares